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Abstract
Composite binary endpoints are increasingly used as primary endpoints in clinical trials. When designing a trial, it
is crucial to determine the appropriate sample size for testing the statistical differences between treatment groups for
the primary endpoint. As shown in this work, when using a composite binary endpoint to size a trial, one needs to
specify the event rates and the effect sizes of the composite components as well as the correlation between them. In
practice, the marginal parameters of the components can be obtained from previous studies or pilot trials, however,
the correlation is often not previously reported and thus usually unknown. We first show that the sample size for
composite binary endpoints is strongly dependent on the correlation and, second, that slight deviations in the prior
information on the marginal parameters may result in underpowered trials for achieving the study objectives at a
pre-specified significance level.
We propose a general strategy for calculating the required sample size when the correlation is not specified, and
accounting for uncertainty in the marginal parameter values. We present the web platform CompARE to characterize
composite endpoints and to calculate the sample size just as we propose in this paper. We evaluate the performance
of the proposal with a simulation study, and illustrate it by means of a real case study using CompARE.
Keywords: Composite Binary Endpoints, Correlated Endpoints, Sample Size.
1. Introduction
Many trials are designed to evaluate more than one endpoint with the aim of providing a wider picture of the
intervention effects [1, 2]. When the rate of occurrence of an event is expected to be low, it is common to consider
the composite event defined as the occurrence of any of a set of pre-specified events. This composite event is usually
chosen as the primary efficacy endpoint for comparing two treatment groups, either by comparing proportions between
groups at the end of the study or by using time-to-event analysis. In this paper, we focus on composite binary
endpoints.
Power analysis and its subsequent sample size calculation have been widely discussed in the literature on compar-
ing two proportions in the univariate case [3, 4, 5, 6]. These standard sample size formulae are based on the effect size
and the frequency of occurrence of primary endpoint, and they could be applied in a straightforward way to a compos-
ite endpoint if its effect size and frequency are known prior to the initiation of the study. However, the effect size and
frequency of observing the composite endpoint depend on the corresponding effect and frequency of the composite
components, which are often quite dissimilar and thus make the composite parameters very difficult to anticipate.
The TACTICS-TIMI 18 trial [7] illustrates some problems that might arise when determining the sample size for a
primary composite binary endpoint. TACTICS-TIMI 18 was an international, multicenter, randomized trial that eval-
uated the efficacy of invasive and conservative treatment strategies in patients with unstable angina or non-Q-wave
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acute myocardial infarction treated with tirofiban, heparin, and aspirin. The primary hypothesis of the TACTICS-
TIMI 18 trial was that an early invasive strategy would reduce the combined incidence of death, acute myocardial
infarction, and rehospitalization for acute coronary syndromes at six months when compared with an early conserva-
tive strategy. The primary endpoint was the composite endpoint formed by death, non-fatal myocardial infarction, and
rehospitalization for acute coronary syndrome at 6 months.
Similar research questions such as those in TACTICS-TIMI 18 were previously investigated in the TIMI IIIB
and VANQWISH trials[8]. The TIMI IIIB trial [9] considered the primary composite endpoint of death, post-
randomization myocardial infarction, and a positive exercise test at 6 weeks; whereas the primary endpoint in the
VANQWISH trial [10] was the combination of death and non-fatal myocardial infarction at 12 months of follow-up.
The initial planning of TACTICS-TIMI 18 was based on those trials expecting 22% events of the primary composite
endpoint in the conservative-strategy group, to detect a relative difference of 25% between the two groups for a 80%
power. Those anticipated values resulted in the need to recruit at least 1720 patients. However, TACTICS-TIMI 18
yielded a 19% frequency of observing the combination of death, acute myocardial infarction and rehospitalization at
six months, which was remarkably lower than expected and delivered a relative difference of 20% between groups, a
figure that is seriously lower than the anticipated 25%. Note that if the anticipated frequency of observing the compos-
ite endpoint had been closer to the observed results, at least 2000 patients rather than 1720 would have been required
and the sample size needed would have been larger than the one initially planned.
In this paper, we present sample size formulations for detecting a hypothesized difference between treatments in
a primary composite binary endpoint based on the event rates and effect sizes of the composite components. The
motivation for this is mainly because prior information on the marginal effects and event rates is commonly available
from previous or pivotal studies, as illustrated in the TACTICS-TIMI 18 trial. Moreover, the major findings in a
trial with a primary composite endpoint should be well supported by its components [1, 11], since the trial could be
considered negative if the components are not in line with the result [12, 13]. Nevertheless, as shown in this paper,
the sample size calculation for composite endpoints relies not only on the anticipation of the effect size and the event
rates of the composite components, but also on the correlation between them. However, even though the marginal
parameters could be obtained previously, the correlation is usually not reported in practice and, thus, is frequently
unknown and difficult to anticipate.
Several authors have addressed the correlation’s influence on sample size determination when more than one
endpoint is used as the primary endpoint. Sozu et al. [14] discuss several methods for calculating power and sample
size for multiple co-primary binary endpoints, and they study the impact on the sample size, specifically regarding the
association among endpoints. Senn and Bretz[15] examine sample size for trials under different power definitions for
multiple testing problems. Rauch and Kieser [16] and Sander et al. [17] define a multiple test procedure focused on a
composite binary endpoint and a pre-specified main component, and propose an internal pilot study for estimating the
unknown parameters and revising the sample size. However, to the best of our knowledge, methodologies are limited
in regard to handling the sample size calculation for composite binary endpoints when the correlation is unknown.
The aim of this paper is two-fold. First, we focus on providing a general procedure for sizing trials with composite
binary endpoints, doing so on the basis of anticipated information of the composite components even if the correlation
is unknown. We show that the sample size for composite binary endpoints is strongly dependent on the correlation, and
that slight deviations in the prior information on the marginal parameters may result in trials being too underpowered
for achieving the study objectives at the pre-specified significance level. We propose a sample size strategy to calculate
the minimum sample size that guarantees the planned power while accounting for, on the one hand, the uncertainty
of the correlation value and, on the other, plausible deviations in the marginal parameter values. Second, we present
CompARE, a freely available web-based tool for characterizing binary composite endpoints and computing the needed
sample size under several settings. CompARE provides aids to help understand the role played by each one of the
components of the composite endpoint, as well as their consequences on the required sample size. The methodologies
presented in this paper have been implemented in CompARE.
This paper is structured as follows. In Section 2, we introduce the settings of the problem and the CompARE
web tool. In Section 3, we review sample size planning when evaluating risk difference. In Section 4, we present
sample size formulae for composite binary endpoints based on the parameters of the components plus the correlation.
We further describe the performance of these formulae according to the parameters and propose a strategy for sizing
trials when the correlation is unknown. In Section 5, we exemplify the proposal by the TACTICS-TIMI 18 trial
using CompARE, and in Section 6 we extend the proposal to those trials for which the treatment effect is measured
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by the relative risk or odds ratio. In Section 7, we investigate the performance of the power and significance level
under misspecification of the correlation and evaluate the proposed sample size strategy with a simulation study. We
conclude the paper with the Discussion.
2. Notation, assumptions and CompARE
We consider a randomized clinical trial comparing two treatment groups: the control group (i = 0) and treatment
group (i = 1), each one composed of n(i) patients who are followed for a pre-specified time τ. For simplicity, we
consider only two events of potential interest, ε1 and ε2. Let Xi jk denote the response of the k-th binary endpoint for
the j-th patient in the i-th group of treatment (i = 0, 1, j = 1, ..., n(i), k = 1, 2). The response Xi jk is defined by 1 if the
event, εk, has occurred during the follow-up and 0 otherwise.
We define the binary composite endpoint as the event that occurs whenever one of the endpoints is observed,
that is, ε∗ = ε1 ∪ ε2. At this point we assume that the composite endpoint is well-defined, that is, both composite
components are important enough to be considered; and we include those adverse clinical outcomes that are relevant to
the clinical setting. We denote by Xi j∗ the composite response defined as a Bernoulli random variable with probability
of observing the event
p
(i)
∗ = P(Xi j∗ = 1) = 1 − q(i)∗ , where:
Xi j∗ =
1, if Xi j1 + Xi j2 ≥ 10, if else Xi j1 + Xi j2 = 0 (1)
To evaluate whether there is a risk reduction in the treatment group compared with the control group, we set
a hypothesis test where the null hypothesis states that there is no difference between the control and the treatment
groups; whereas the alternative hypothesis assumes a risk reduction in the treatment group. The usual measures to
evaluate the treatment effect when comparing two groups are the difference in proportions (also called risk difference),
denoted by δ∗; the relative risk (or risk ratio), R∗; and the odds ratio, OR∗. The relationship between these measures
and the probabilities of observing the binary composite endpoint in each group are given in Table 1, together with the
null and alternative hypothesis that should be set in each case. The following sections will be developed in terms of
the risk difference δ∗ = p
(1)
∗ − p(0)∗ of the composite binary endpoint. Section 6 extends the results to the relative risk
and odds ratio.
Table 1: Parameter to anticipate the effect, and set of hypotheses.
Parameter Effect Null hypothesis Alternative hypothesis
Risk difference δ∗ = p
(1)
∗ − p(0)∗ δ∗ = 0 δ∗ < 0
Relative risk R∗ = p
(1)
∗ /p
(0)
∗ log(R∗) = 0 log(R∗) < 0
Odds ratio OR∗ =
p
(1)
∗ /q
(1)
∗
p
(0)
∗ /q
(0)
∗
log(OR∗) = 0 log(OR∗) < 0
2.1. An insight into the parameters of the composite endpoint
Let p
(i)
k
and q
(i)
k
represent the probabilities that εk occurs or not, respectively, for a patient belonging to the i-th
group. Let ρ(i) denote Pearson’s correlation coefficient between the components in the i-th group. The probability of
observing the composite event ε∗ is in terms of the probabilities of ε1 and ε2 and the correlation, as follows:
p
(i)
∗ = 1 − q(i)1 q(i)2 − ρ(i)
√
p
(i)
1
p
(i)
2
q
(i)
1
q
(i)
2
, i = 0, 1 (2)
Note here that the probability of observing the composite endpoint becomes smaller as the correlation between the
components of the composite increases.
The effect size in the composite endpoint in terms of the risk difference, δ∗, is given by:
δ∗ = δ1q
(0)
2
+ δ2q
(0)
1
− δ1δ2 + ρ(0)
√
p
(0)
1
p
(0)
2
q
(0)
1
q
(0)
2
− ρ(1)
√
(p
(0)
1
+ δ1)(p
(0)
2
+ δ2)(q
(0)
1
− δ1)(q(0)2 − δ2) (3)
3
where δk (k = 1, 2) corresponds to the risk difference for each of its components.
From now on the correlation is assumed equal for both groups and denoted by ρ, that is, ρ = ρ(0) = ρ(1). Let θ
denote the vector of event rates of the composite components in the control group, that is, θ = (p
(0)
1
, p
(0)
2
), and let λ
represent the vector of marginal effect sizes, that is, λ = (δ1, δ2). We will denote the risk difference as a function of the
marginal parameters (θ, λ) and the correlation ρ by δ∗(θ, λ, ρ); and the probability of observing ε∗ under the control
group by p
(0)
∗ (θ, ρ). We remark here that when λ and θ are fixed such that p
(0)
k
< 0.5 and δk < 0 (k = 1, 2), the risk
difference δ∗(θ, λ, ρ) increases with respect to the correlation ρ (see Appendix Appendix A).
2.2. CompARE
We present CompARE1, an open-source and completely free web platform that can be used as a tool for clinicians,
medical researchers and statisticians to compute the sample size according to the procedure proposed in this paper.
Furthermore, CompARE can be used to:
1. Determine the sample size for different situations, among them, when the correlation is not known.
2. Specify the treatment effect for the composite endpoint based on the marginal information of the composite
components, and to study the performance of the composite parameters according to them.
3. Calculate and interpret the measures of association among the composite components, then investigate their
characteristics.
4. Choose the best primary endpoint to lead the trial. CompARE computes the Asymptotic Relative Efficiency
method[18, 19], which quantifies differences in the efficiency of using – as the primary endpoint – a composite
endpoint over one of its components.
Figure 1 summarizes all the capabilities of CompARE. To use CompARE, the least you should provide is the effect
size and event rates of the composite components as well as the correlation.
3. Sample Size when the parameters of the composite endpoint can be anticipated
In this section we summarize the statistics and sample size formulae to test for a risk difference when the proba-
bility of occurrence in the control group of the composite binary endpoint can be anticipated and for a given expected
risk difference. Since the composite endpoint is an univariate outcome, a single statistical test is performed and,
consequently, no multiplicity problem occurs and no statistical adjustment is needed. Therefore, as we will see, the
formulas follow the univariate case and are straightforward but to make the paper comprehensive and the following
sections meaningful, we displayed them in terms of the composite endpoint parameters.
Herein we assume a clinical trial where, first, patients are randomized to one of two treatment arms following
a balanced design and, second, where the primary endpoint is a binary composite endpoint. The aim is to detect a
hypothesized risk reduction in the primary composite endpoint at the significance level of α and with desired power
equal to 1 − β. Let n be the total sample size required, with n(i) = n/2 patients per group (i = 0, 1); and let us denote
by zα and zβ the values of standardized normal deviates corresponding to α and β.
The null hypothesis is stated as H∗0 : p
(1)
∗ − p(0)∗ = 0 and is compared against the alternative hypothesis H∗1 :
p
(1)
∗ − p(0)∗ < 0. To test H∗0 against H∗1 we use the statistic:
T∗,n =
p̂
(1)
∗ − p̂(0)∗√
V̂ar( p̂
(1)
∗ − p̂(0)∗ )
(4)
1Link to CompARE: https://cinna.upc.edu/compare/ , the open-source code for CompARE is available at:
https://github.com/MartaBofillRoig/CompARE
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Figure 1: Scheme of the main lines of action in CompARE. Link to the CompARE homepage: http://cinna.upc.edu/compare/ . Open-source
code is available at: https://github.com/MartaBofillRoig/CompARE .
where p̂
(i)
∗ =
1
n(i)
∑n(i)
j=1 Xi j∗. Under H
∗
0, T∗,n follows, asymptotically, the standard normal distribution. We will reject
the null hypothesis at the α level of significance if T∗,n < −zα. The variance Var( p̂(1)∗ − p̂(0)∗ ) in equation (4) can be
estimated under H∗0 using the pooled variance estimate[4]:
V̂arH0( p̂
(1)
∗ − p̂(0)∗ ) =
1
2n(0)
·
(
p̂
(0)
∗ + p̂
(1)
∗
)
·
(̂
q
(0)
∗ + q̂
(1)
∗
)
or under H∗1 using the unpooled variance estimate:
V̂arH1( p̂
(1)
∗ − p̂(0)∗ ) =
1
n(0)
(
p̂
(0)
∗ q̂
(0)
∗ + p̂
(1)
∗ q̂
(1)
∗
)
For a given probability under control group p
(0)
∗ , the required sample size using the pooled estimate to have power
1 − β in order to detect an effect size of δ∗ at a significance level α is given by [3, 5]:
n = 2 ·
(
zα ·
√
(2p
(0)
∗ + δ∗)(2q
(0)
∗ − δ∗) + zβ ·
√
p
(0)
∗ q
(0)
∗ + (p
(0)
∗ + δ∗)(q
(0)
∗ − δ∗)
)2 /
δ2∗ (5)
Note that in (5) we have replaced p
(1)
∗ with p
(0)
∗ + δ∗.
Similarly, the corresponding sample size using the unpooled variance estimate is given by:
n = 2 ·
(
zα + zβ
δ∗
)2
·
(
p
(0)
∗ q
(0)
∗ + (p
(0)
∗ + δ∗)(q
(0)
∗ − δ∗)
)
(6)
Note that, under the null hypothesis H∗0 : p
(1)
∗ − p(0)∗ = 0, expressions (5) and (6) coincide.
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4. Sample Size based on anticipated values of the composite components
Sample size formulae underlined in Section 3 are based on the parameters of the composite endpoint, that is, the
event rate under the control group, p
(0)
∗ , and the treatment effect, δ∗. In this section, we derive the sample size based
on the anticipated information on the marginal parameter values and the correlation, even if the correlation value is
not fully specified and/or the event rates values are not accurately anticipated.
4.1. Sample size based on composite components
Given the event rates in the control group θ = (p
(0)
1
, p
(0)
2
), the expected effect size for each component λ = (δ1, δ2),
and the correlation between the occurrence of both components ρ, we will denote by n(θ, λ, ρ) the needed sample size,
which is computed by using the unpooled variance estimate, to detect a risk difference δ∗(θ, λ, ρ) (see equation (3)) at
significance level α with 1 − β power.
The expression for n(θ, λ, ρ) is obtained after direct substitution into formula (6) and is as follows:
n(θ, λ, ρ) =
2 ·
(
zα + zβ
)2 · (p(0)∗ (θ, ρ) (1 − p(0)∗ (θ, ρ)) + (p(0)∗ (θ, ρ) + δ∗(θ, λ, ρ)) (1 − p(0)∗ (θ, ρ) − δ∗(θ, λ, ρ)))
δ∗(θ, λ, ρ)2
(7)
where p
(0)
∗ (θ, ρ) is given in (2). Note that the sample size also relies on the significance level α and the power 1−β, but
these are omitted for ease of notation. The corresponding sample size under the pooled estimate can be analogously
calculated by using θ, λ and ρ and its expression can be found in the online support material.
4.2. Sample size bounds
Assuming that the correlation is the same in the two treatment groups, it follows that the correlation takes values
between the lower bound, BL(·), and the upper bound, BU(·), which are functions of θ and λ, and are defined as:
BL(θ, λ) = max
−
√
p
(0)
1
· p(0)
2
q
(0)
1
· q(0)
2
, −
√
q
(0)
1
· q(0)
2
p
(0)
1
· p(0)
2
, −
√
(p
(0)
1
+ δ1) · (p(0)2 + δ2)
(q
(0)
1
− δ1) · (q(0)2 − δ2)
, −
√
(q
(0)
1
− δ1) · (q(0)2 − δ2)
(p
(0)
1
+ δ1) · (p(0)2 + δ2)
 (8)
BU(θ, λ) = min
+
√
p
(0)
1
· q(0)
2
p
(0)
2
· q(0)
1
, +
√
p
(0)
2
· q(0)
1
p
(0)
1
· q(0)
2
, +
√
(p
(0)
1
+ δ1) · (q(0)2 − δ2)
(p
(0)
2
+ δ2) · (q(0)1 − δ1)
, +
√
(p
(0)
2
+ δ2) · (q(0)1 − δ1)
(p
(0)
1
+ δ1) · (q(0)2 − δ2)

Note that when at least one of the event rates is very close to 0, the lower bound BL(λ, θ) will also be close to 0 and the
plausible correlation values will be always positive. We also notice that, in clinical trials the probabilities of observing
the events are often quite low and commonly smaller than 0.5. In this case, the expressions for BL(λ, θ) and BU(λ, θ)
can be simplified. See the online supplementary material for more details.
Considering such bounds for a given marginal parameters θ and λ, the sample size n(θ, λ, ρ) is an increasing func-
tion of the correlation ρ, and it is bounded below and above by n(θ, λ, BL(θ, λ)) and n(θ, λ, BU(θ, λ)), respectively. As
a consequence, the more correlated the single endpoints are, the larger will be the necessary sample size for detect-
ing the differences between groups in the composite endpoint. Details for this derivation are provided in Appendix
Appendix B (see Theorem 1).
4.3. Sample size with uncertain correlation value
Since the correlation plays an important role in calculating the sample size, we propose a strategy for deriving the
sample size when the parameters that correspond to the composite components are known and the correlation value is
not specified in advance.
Prior knowledge about the effect of the treatment being investigated can lead to scientists foreseeing whether the
two events of interest, ε1 and ε2, are weakly, moderately or strongly correlated. We allow for prior information by
splitting the rank of the correlation into three equal-sized intervals, and we consider three correlations categories:
weak for the interval whose correlation values are lower; moderate for those intermediate correlation values; and
strong for those correlation values that are higher. If any information exists, we will take it into account and will
proceed as follows:
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(i) Correlation bounds for each category:
Considering the categories weak/moderate/strong for the correlation, the plausible correlation values for a given
(θ, λ) are in this situation those between the lower and upper values within each category. If the events are weakly
correlated, the correlation is between BL(θ, λ) and (BU(θ, λ) − BL(θ, λ))
/
3; if they are moderately correlated, its
value lies between (BU(θ, λ) − BL(θ, λ))
/
3 and 2 · (BU(θ, λ) − BL(θ, λ))
/
3; and if they are strongly correlated, it
is between 2 · (BU(θ, λ) − BL(θ, λ))
/
3 and BU(θ, λ).
If we cannot place the correlation in any of the above categories, we use the most severe case within its plausible
values, then, BU(θ, λ). (See Table 2).
(ii) Calculate the sample size in each category:
For the sample size, we advocate using the maximum sample size across all its possible values. That is,
n(θ, λ, (BU(θ, λ) − BL(θ, λ))
/
3), n(θ, λ, 2 (BU(θ, λ) − BL(θ, λ))
/
3), and n(θ, λ, BU(θ, λ)) for weak, moderate or
strong correlations, respectively. Note that since we are assuming the correlation value that maximizes the
sample size across its plausible values, we are guaranteeing that the pre-specified power 1 − β is attained.
If the correlation value can not be ascribed to any category, then, we propose a conservative sample size strat-
egy of using the overall possible maximum sample size, that is, n(θ, λ, BU(θ, λ)). Table 2 outlines the range of
correlations and sample sizes values, together with the proposed sample size for each category.
Table 2: Correlation category and its subsequent correlation bounds, BL(·) and BU(·) (given in (8)) for event rates of the composite components
θ = (p
(0)
1
, p
(0)
2
), and marginal effect sizes λ = (δ1, δ2). Sample size bounds for each correlation category and proposed sample size strategy
calculated by (7) according to the margins (θ, λ) and for given significance level α and power 1 − β.
Category Correlation Bounds Sample Size Bounds Sample Size
Weak
[
BL(θ, λ),
(BU (θ,λ)−BL(θ,λ))
3
) [
n(θ, λ, BL(θ, λ)), n
(
θ, λ,
(BU (θ,λ)−BL(θ,λ))
3
) ]
n
(
θ, λ,
(BU (θ,λ)−BL(θ,λ))
3
)
Moderate
[
(BU (θ,λ)−BL(θ,λ))
3
,
2(BU (θ,λ)−BL(θ,λ))
3
) [
n
(
θ, λ,
(BU (θ,λ)−BL(θ,λ))
3
)
, n
(
θ, λ,
2(BU (θ,λ)−BL(θ,λ))
3
) ]
n
(
θ, λ,
2(BU (θ,λ)−BL(θ,λ))
3
)
Strong
[
2(BU (θ,λ)−BL(θ,λ))
3
, BU(θ, λ)
) [
n
(
θ, λ,
2(BU (θ,λ)−BL(θ,λ))
3
)
, n(θ, λ, BU(θ, λ))
]
n(θ, λ, BU(θ, λ))
No prior information [BL(θ, λ), BU(θ, λ))
[
n(θ, λ, BL(θ, λ)), n (θ, λ, BU(θ, λ))
]
n (θ, λ, BU(θ, λ))
4.4. Sample size accounting for departures from the anticipated event rates
The marginal parameters are often estimated through previous studies or pivotal trials with a limited number of
patients and whose patient populations or concomitant drugs could differ from the current ones. Because of that, there
is great uncertainty in the values that need to be anticipated for computing the sample size. In this section, we consider
that the event rates p
(0)
1
and p
(0)
2
have been previously estimated and their corresponding standard errors of the point
estimate are provided.
Let Ik =
[
p(0)
k
, p¯
(0)
k
]
denote a set of plausible values for the true value of p
(0)
k
. For instance, for those previous trials
in which we have the standard deviations for the event rates, we can use the set of plausible values for p
(0)
k
that a 95%
confidence interval would yield. We address the issue of sizing a trial for a significance level α and power 1− β based
on the intervals I1 and I2, and for fixed effects δ1 and δ2 when the correlation value is not known.
We state that, for given δ1 and δ2 and at fixed ρ = r, the sample size n(p
(0)
1
, p
(0)
2
, λ, r) (see equation (7)) that is
needed for power 1 − β at a significance level α, falls into the interval:
I(r, I1, I2, λ) = [ n(p(0)
1
, p(0)
2
, λ, r), n( p¯
(0)
1
, p¯
(0)
2
, λ, r) ] (9)
This interval is such that it contains the sample size required to attain power 1−β, which is necessary for detecting
an effect size equal to δ∗ = p
(1)
∗ − p(0)∗ at a significance level α according to the marginal effects δ1 and δ2, the
correlation r, and the event rates p
(0)
k
within Ik (k = 1, 2). Note that the interval I(r, I1, I2, λ) gives us the plausible
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sample size values by taking into account the uncertainty of the marginal parameter values, and it provides us the
maximum sample size that we would need even though the anticipated event rates are not accurate.
ConsideringΘ = (I1, I2, λ) the set of values for the marginal parameters, and denoting by ρL(Θ) = max(π1 ,π2)∈I1×I2 BL(π1, π2, λ)
and ρU (Θ) = min(π1 ,π2)∈I1×I2 BU(π1, π2, λ) the lower and upper bounds of the correlation within the set Θ. Then, for all
(π1, π2) ∈ I1 × I2, and ρ ∈ (ρL(Θ), ρU(Θ)), we have that:
n(π1, π2, λ, ρ) ≤ U(Θ) = n( p¯(0)1 , p¯(0)2 , λ, ρU(Θ)) (10)
Furthermore, for given p¯
(0)
1
, p¯
(0)
2
, λ, the sample size n( p¯
(0)
1
, p¯
(0)
2
, λ, ρ) is an increasing function of the correlation ρ.
The sample size given by n( p¯
(0)
1
, p¯
(0)
2
, λ, ρ) delimits the values that the sample size could have in terms of the
correlation accounting for plausible deviations in the anticipated event rates. If there is no prior information on
the correlation, we can use U(Θ) as the needed sample size. If otherwise, we have some prior information on the
correlation value, the rationale used in 4.3 using correlation categories can be as well applied here to the function
n( p¯
(0)
1
, p¯
(0)
2
, λ, ρ). Table 3 provides the sample size strategy under this circumstance. We lay out the performance of the
sample size when varying the event rates in the intervals I1 and I2 and the subsequent sample size behavior according
to the correlation in Propositions 2 and 3 in the supplementary material.
Table 3: Correlation category and its subsequent correlation bounds, ρL(·) and ρU (·) for the intervals of plausible values for event rates, I1 =[
p(0)
1
, p¯
(0)
1
]
and I2 =
[
p(0)
2
, p¯
(0)
2
]
, and marginal effect sizes λ = (δ1, δ2), and where Θ = (I1, I2, λ) denotes the set of values for the marginal
components. Sample size bounds for each correlation category and proposed sample size strategy calculated by (7) according to the intervals I1
and I2, the marginal effect sizes λ, for given significance level α and power 1 − β.
Category Correlation Bounds Sample Size Bounds Chosen Sample Size
Weak
[
ρL(Θ),
ρU (Θ)−ρL(Θ)
3
) [
n(p(0)
1
, p(0)
2
, λ, ρL(Θ)), n
(
p¯
(0)
1
, p¯
(0)
2
, λ,
ρU (Θ)−ρL(Θ)
3
) ]
n
(
p¯
(0)
1
, p¯
(0)
2
, λ,
ρU (Θ)−ρL(Θ)
3
)
Moderate
[
ρU (Θ)−ρL(Θ)
3
,
2(ρU (Θ)−ρL(Θ))
3
) [
n
(
p(0)
1
, p(0)
2
, λ,
ρU (Θ)−ρL(Θ)
3
)
, n
(
p¯
(0)
1
, p¯
(0)
2
, λ,
2(ρU (Θ)−ρL(Θ))
3
)]
n
(
p¯
(0)
1
, p¯
(0)
2
, λ,
2(ρU (Θ)−ρL(Θ))
3
)
Strong
[
2(ρU (Θ)−ρL(Θ))
3
, ρU(Θ)
) [
n
(
p(0)
1
, p(0)
2
, λ,
2(ρU (Θ)−ρL(Θ))
3
)
, n( p¯
(0)
1
, p¯
(0)
2
, λ, ρU (Θ))
]
n( p¯
(0)
1
, p¯
(0)
2
, λ, ρU(Θ))
No prior information
[
ρL(Θ), ρU(Θ))
[
n
(
p(0)
1
, p(0)
2
, λ, ρL(Θ)
)
, n
(
p¯
(0)
1
, p¯
(0)
2
, λ, ρU(Θ)
) ]
n
(
p¯
(0)
1
, p¯
(0)
2
, λ, ρU (Θ)
)
4.5. Power performance of the proposed strategies
Given (θ, λ, ρ) and for a fixed sample size N, the power function using the unpooled variance estimate is defined
as:
ψ(θ, λ, ρ,N) = Φ

√
N · δ∗(θ, λ, ρ)√
p
(0)
∗ (θ, ρ)
(
1 − p(0)∗ (θ, ρ)
)
+
(
p
(0)
∗ (θ, ρ) + δ∗(θ, λ, ρ)
) (
1 − p(0)∗ (θ, ρ) − δ∗(θ, λ, ρ)
) − zα
 (11)
whereΦ(·) denotes the cumulative distribution of the standard normal distribution. The power function for the pooled
variance estimator can be found in the online support material.
In what follows, we show that the planned power 1−β is achievedwith any of the previous strategies in Subsections
4.3 and 4.4.
• If θ and λ are fixed and the correlation value is not known, we have n(θ, λ, ρ) ≤ n(θ, λ, BU(θ, λ)) and the proposed
sample size becomes N = n
(
θ, λ, BU(θ, λ)
)
. The resulting power is then such that:
ψ
(
θ, λ, ρ, n
(
θ, λ, BU(θ, λ)
)) ≤ ψ (θ, λ, ρ, n(θ, λ, ρ)) .
The power attained using the upper bound of the correlation is equal to the pre-specified power value (1 − β)
when the correlation ρ is the maximum value within its range, that is, BU(θ, λ). Otherwise, if the correlation
is less than BU(θ, λ), the power will be always higher than the pre-specified power. Table S1 in the online
supplementary material details the power performance when the correlation categories are taken into account.
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• If the event rate value p
(0)
k
is within the interval Ik for k = 1, 2 and the effect sizes λ are fixed, then n(p
(0)
1
, p
(0)
2
, λ, ρ) ≤
n
(
p¯
(0)
1
, p¯
(0)
2
, λ, ρ
)
. If in addition we have no prior information on the correlation value, then since the sample size
increases with respect to the correlation, it follows that n
(
p¯
(0)
1
, p¯
(0)
2
, λ, ρ
) ≤ n(p¯(0)
1
, p¯
(0)
2
, λ, ρU(Θ)
)
, and then the
proposed sample size turns into N = n
(
p¯
(0)
1
, p¯
(0)
2
, λ, ρU(Θ)
)
. The corresponding power then satisfies:
ψ
(
θ, λ, ρ, n
(
p¯
(0)
1
, p¯
(0)
2
, λ, ρU(Θ)
)) ≤ ψ (θ, λ, ρ, n(p(0)
1
, p
(0)
2
, λ, ρ)
)
.
The power attained is equal to the pre-specified power value when the event rates p
(0)
k
take the upper values
p¯
(0)
k
and the correlation ρ is equal to ρU(Θ). If that is not the case, the power obtained will be larger than the
pre-specified 1 − β.
5. Motivating example: TACTICS-TIMI 18 trial
In managing the syndrome of unstable angina and non-Q-wave acute myocardial infarction, there is controversy
over whether using an invasive strategy rather than a conservative strategy offers any advantage. TACTICS-TIMI 18
was a randomized trial that evaluated the efficacy of invasive and conservative treatment strategies in patients with
unstable angina and non-Q-wave AMI treated with tirofiban, heparin, and aspirin [7].
Patients were randomly assigned to either an early invasive strategy or an early conservative strategy. The primary
hypothesis of the TACTICS-TIMI 18 trial was that an early invasive strategy would reduce the combined incidence of
death, acute myocardial infarction, and rehospitalization for acute coronary syndromes at six months when compared
with an early conservative strategy. The primary endpoint was the composite endpoint formed by a combination of
incidence of death or non-fatal myocardial infarction (ε1), and rehospitalization for acute coronary syndrome (ε2) at
six months.
For illustrative purposes, we assume that a trial will be planned for a similar setting and that the results of
TACTICS-TIMI 18 are to be used. Since previous studies to TACTICS-TIMI 18 also considered the events death
and non-fatal myocardial infarction altogether, we presume that the event rate and effect size on the endpoint ε1
can be anticipated despite being composed by two events. The estimated values for the frequency of death or non-
fatal myocardial infarction (ε1) in the conservative strategy group was pˆ
(0)
1
= 0.095 with a standard deviation of
0.009; whereas the frequency of rehospitalization for acute coronary syndrome (ε2) was pˆ
(0)
2
= 0.137 with a standard
deviation of 0.010. Based on the standard deviations of the estimated event rates, we use the 95% confidence inter-
vals as a set of plausible values among which the true values p
(0)
1
, p
(0)
2
take values, that is, I1 = [0.078, 0.112] and
I2 = [0.117, 0.157]. The observed effects on TACTICS-TIMI 18 were δ1 = −0.022 and δ2 = −0.027, and we will use
these as the expected effects on the new experimental trial.
We consider these parameters to construct the correlation bounds outlined in equation (8). The effects δ1 and δ2
and the values pˆ
(0)
1
and pˆ
(0)
2
imply that the eligible values for ρ lie in the interval (−0.10, 0.80). Using the intervals
I1 and I2, the correlation bounds are such that the considered values are plausible for any event rate within I1 and I2.
This gives us the correlation bounds (−0.08, 0.77). Table 4 and its accompanying figure show the correlation bound
according to δ1 and δ2 with varying values of the event rates. Observe that the upper bound takes the value 1 when
both event rates are equal, and the lower bound tends to 0 when at least one of the event rates becomes smaller.
We illustrate the aspects of calculating power and sample size using the platformCompARE. CompARE calculates
the sample size by anticipating the marginal information in terms of either risk difference, relative risk, or odds ratio.
In this particular case, we use the statistical test for risk difference under pooled variance in order to ascertain the
treatment differences in the composite endpoint at a significance level of α = 0.025 and target power of 1 − β = 0.80.
The results obtained from CompARE are presented in the form of summary tables and plots.
Figure 2 (left panel) depicts the performance of the sample size in terms of the correlation for given marginal
parameters θ = ( pˆ
(0)
1
, pˆ
(0)
2
) and λ = (δ1, δ2); and it illustrates the recommended sample size for each correlation
category (weak, moderate, and strong). The solid line represents the sample size as a function of the correlation
computed for the anticipated values θ, and the shaded areas represent the region of values, constructed by I1, I2, δ1
and δ2, within which interval the sample size falls. Based on I1 and I2 the proposed sample size (in dotted lines) is the
upper value of the shaded area within the correlation category.
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Event rate values Correlation Bounds
pˆ
(0)
1
= 0.095, pˆ
(0)
2
= 0.137 −0.10 ≤ ρ ≤ 0.80
p¯
(0)
1
= 0.112, p¯
(0)
2
= 0.157 −0.12 ≤ ρ ≤ 0.81
p(0)
1
= 0.078, p(0)
2
= 0.117 −0.08 ≤ ρ ≤ 0.77
Table 4: Lower bound, BL(θ, λ), and upper bound, BU (θ, λ), for the
correlation according to the effect sizes δ1 = −0.022, δ2 = −0.027
and for different values of the event rates.
FIGURE Lower bound (surface in blue) and upper bound (in red)
for the correlation according to the effect sizes δ1 = −0.022, δ2 =
−0.027 and where the marginal event rates take values between 0
and 0.2.
Note that the sample size is highly sensitive to the anticipated parameters. For instance, for ρ = 0.3, using pˆ
(0)
1
and pˆ
(0)
2
, the required sample size is n = 3030. This sample size, however, can differ substantially from that calculated
using other reasonable values, such as the upper or lower limits for the intervals I1 and I2, which would imply n = 2511
and n = 3540, respectively.
Figure 2 (right panel) describes the statistical power achieved under the proposed method. Assuming that we have
correctly anticipated the correlation category, observe that in all cases the achieved power is larger than the planned
power, 1 − β. Then, the method guarantees the desired power. If we could correctly anticipate the values of the event
rates, then the achieved power would lie between 0.80 and 0.87, in accordance with the plausible correlation values.
If we base the sample size calculation on the intervals I1 and I2, we will be overestimating the statistical power more
than in the previous case, thus obtaining a power between 0.80 and 0.95.
Table 5 describes the proposed sample size for each correlation category and reports the possible values for the
statistical power, assuming that we have correctly anticipated the correlation category.
Table 5: Recommended sample size for testing differences between the invasive strategy as compared with the conservative strategy. Underlying
marginal parameters are as follows: p
(0)
1
= 0.095, p
(0)
2
= 0.137, δ1 = −0.022, δ2 = −0.027. Both sample size and power were calculated based
on the statistic (4) under the pooled variance for a one-sided test at the significance level of α = 0.025. The given sample size was calculated to
detect the effect on the composite endpoint with the desired overall power of 1 − β = 0.80. For calculating the power of the test, three sample size
situations were considered, depending on the strength of the correlation: i) weak correlation; ii) moderate correlation; iii) strong correlation.
Based on point values p
(0)
1
= 0.095, p
(0)
2
= 0.137 for the event rates:
Correlation bounds: BL(θ, λ) = −0.10, BU(θ, λ) = 0.80.
Association strength Correlation Sample size Achieved power
Weak −0.10 ≤ ρ ≤ 0.20 2860 (0.80, 0.86)
Moderate 0.20 < ρ ≤ 0.50 3425 (0.80, 0.87)
Strong 0.50 < ρ ≤ 0.80 4201 (0.80,0.87)
Based on intervals I1 = [0.078, 0.112] and I2 = [0.117, 0.157] for the event rates:
Correlation bounds: ρL(Θ) = −0.08, ρU(Θ) = 0.77.
Association strength Correlation Sample size Achieved power
Weak −0.08 ≤ ρ ≤ 0.21 3355 (0.80, 0.95)
Moderate 0.21 < ρ ≤ 0.49 3970 (0.80, 0.95)
Strong 0.49 < ρ ≤ 0.77 4782 (0.80, 0.95)
10
Figure 2: Sample size (left panel) and power (right panel) as a function of the correlation according to the marginal effect sizes δ1 = −0.022 and
δ2 = −0.027; either based on the point values pˆ(0)1 = 0.095, pˆ
(0)
2
= 0.137 for the event rates (solid line) or based on the interval of plausible values
for the event rates I1 = [0.078, 0.112] and I2 = [0.117, 0.157] (shaded areas). The proposed sample size for each correlation category is highlighted
in solid and dotted lines for, respectively, the point values and the interval values for the event rates.
6. An extension for risk ratio and odds ratio
In this Section, we show that the risk ratio and odds ratio for the composite endpoint can also be expressed in
terms of its margins plus the correlation, and we extend the sample size derivation given in Section 4 for evaluating
the risk and odds ratio.
6.1. Composite effect expressed in terms of the risk ratio or the odds ratio
Let Rk and ORk denote the risk ratio and odds ratio, respectively, for the k-th event. The risk ratio for the composite
endpoint, R∗, is expressed in terms of the risk ratio of its components R1 and R2, the event rates under control group,
p
(0)
1
and p
(0)
2
, and the correlation between them, ρ, as follows:
R∗ =
p
(0)
1
R1 + p
(0)
2
R2 − p(0)1 p(0)2 R1R2 − ρ
√
p
(0)
1
R1p
(0)
2
R2(1 − p(0)1 R1)(1 − p(0)2 R2)
1 − q(0)
1
q
(0)
2
− ρ
√
p
(0)
1
p
(0)
2
q
(0)
1
q
(0)
2
(12)
Analogously, the odds ratio for the composite endpoint OR∗ is defined according to its margins and the correlation is
given by:
OR∗ =
((
1 +
OR1p
(0)
1
1−p(0)
1
) (
1 +
OR2p
(0)
2
1−p(0)
2
)
− 1 − ρ
√
OR1OR2p
(0)
1
p
(0)
2
(1−p(0)
1
)(1−p(0)
2
)
)
·
(
1 + ρ
√
p
(0)
1
p
(0)
2
(1−p(0)
1
)(1−p(0)
2
)
)
((
1 +
p
(0)
1
(1−p(0)
1
)
)
·
(
1 +
p
(0)
2
(1−p(0)
2
)
)
− 1 − ρ
√
p
(0)
1
p
(0)
2
(1−p(0)
1
)(1−p(0)
2
)
)
·
(
1 + ρ
√
OR1OR2p
(0)
1
p
(0)
2
(1−p(0)
1
)(1−p(0)
2
)
) (13)
The derivations of equations (12) and (13) are postponed to Appendix Appendix A. By inspection of (3), (12), and
(13), we observe that if there is no effect on the components, that is, δ1 = δ2 = 1, R1 = R2 = 1 or OR1 = OR2 = 1,
then there is no effect on the composite endpoint, δ∗ = R∗ = OR∗ = 1. However, the reciprocal does not follow:
no effect on the composite endpoint is compatible with some effect on the components. Therefore, it is important to
remark, as other authors have warned before [21, 22, 23], that not finding a beneficial effect on composite endpoint is
not a guarantee of not having some effect on the components, hence the effect on the composite endpoint cannot be
treated as if it were an indicator of some specific effect on its components.
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6.2. Sample size calculations in terms of risk ratio and odds ratio
The null hypothesis in terms of the risk ratio is stated as H∗0 : log(R∗) = 0 and the alternative hypothesis assuming
a risk reduction is H∗1 : log(R∗) < 0. The statistic that we use for testing the significance of the relative risk R∗ is:
Z∗,n = log(R̂∗)
/√
V̂ar(log(R̂∗))
where R̂∗ = p̂
(1)
∗ / p̂
(0)
∗ . Under H
∗
0, Z∗,n asymptotically follows the standard normal distribution; thus, we will reject H
∗
0
at the α significance level if Z∗,n < −zα. As in Section 3, we estimate the variance Var(R̂∗) using the pooled variance
by means of V̂arH0(log(R̂∗)) =
2
n(0)
· q̂(0)∗ +q̂(1)∗
p̂
(0)
∗ +p̂
(1)
∗
or by using the unpooled variance, V̂arH1(log(R̂∗)) =
1
n(0)
(
1−R̂∗ p̂(0)∗
R̂∗ p̂
(0)
∗
+
q̂
(0)
∗
p̂
(0)
∗
)
.
For a given probability under control group p
(0)
∗ , and a significance level α, the needed sample size for detecting a
risk ratio Γ∗ = p
(1)
∗ /p
(0)
∗ with power 1 − β is given by:
n = 2 ·
(
zα + zβ
)2 · 1 − Γ∗p(0)∗
Γ∗p
(0)
∗
+
q
(0)
∗
p
(0)
∗
 / log(Γ∗)2 (14)
The corresponding sample size when the pooled variance is used can be seen in Table 6.
When measuring the effect of treatment with the odds ratio, the null hypothesis H∗0 : log(OR∗) = 0 is compared
with the alternative hypothesis H∗1 : log(OR∗) < 0. To test the above hypotheses we use the statistic:
W∗,n = log(ÔR∗)
/√
V̂ar(log(ÔR∗))
where ÔR∗ =
p̂
(1)
∗ /q̂
(1)
∗
p̂
(0)
∗ /q̂
(0)
∗
and where the pooled and unpooled variance estimates are given, respectively, by V̂arH0(log(ÔR∗)) =
8
n(0)(p̂
(0)
∗ +p̂
(1)
∗ )(̂q
(0)
∗ +q̂
(1)
∗ )
and V̂arH1(log(ÔR∗)) =
1
n(0)
(
1
pˆ
(0)
∗ qˆ
(0)
∗
+ 1
pˆ
(1)
∗ qˆ
(1)
∗
)
.
Then the needed sample size is calculated using the unpooled variance, for detecting a treatment difference of
OR∗ = ∆∗ in order to have power 1 − β at level α for given p(0)∗ , and it is given by:
n = 2 ·
(
zα + zβ
log(∆∗)
)2
·
 (q(0)∗ + p(0)∗ ∆∗)2
p
(0)
∗ q
(0)
∗ ∆∗
+
1
p
(0)
∗ q
(0)
∗
 (15)
The sample size expression when using the pooled variance can be found in Table 6.
6.3. Sample size derivation based on its margins
Analogously to Section 4 and following the notation in Section 4.4,, we obtain the sample size based on the risk
ratio as a function of the marginal effects R1 and R2, the event rates θ, and the correlation ρ. To do so, we take the event
rate and risk ratio of the composite endpoint for their expressions (which are defined according to θ, R1, R2 and ρ, see
equations (2) and (12)), and then substitute these into the sample size formula in (14). We denote by n(θ,R1,R2, ρ)
the needed sample size for evaluating the risk ratio computed for specific values θ, R1,R2, and ρ. We will analogously
proceed with sample size in terms of the odds ratio using the effects OR1 and OR2, then denote by n(θ,OR1,OR2, ρ)
the corresponding sample size.
In what follows, we describe the performance of the sample size when the effect is measured by odds ratio or risk
ratio. Further details of these properties and their empirical proof are to be found in the web supplementary material.
• For fixed (θ,R1,R2) or (θ,OR1,OR2), the sample size for testing the effect measured by the risk ratio, n(θ,R1,R2, ρ),
and the sample size for testing the odds ratio, n(θ,OR1,OR2, ρ), are increasing functions of the correlation ρ.
• For given R1 and R2 at fixed ρ = r, the needed sample size n(p
(0)
1
, p
(0)
2
,R1,R2, r) to have power 1 − β at a
significance level α falls into the interval:
I(r, I1, I2,R1,R2) = [ n( p¯
(0)
1
, p¯
(0)
2
,R1,R2, r), n(p
(0)
1
, p(0)
2
,R1,R2, r) ] (16)
Analogously, for given OR1 and OR2, the needed sample size n(p
(0)
1
, p
(0)
2
,OR1,OR2, r) lies within the interval:
I(r, I1, I2,OR1,OR2) = [ n( p¯
(0)
1
, p¯
(0)
2
,OR1,OR2, r), n(p
(0)
1
, p(0)
2
,OR1,OR2, r) ]
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Table 6: Formulae for sample size determination when comparing two treatments with respect to difference proportions, relative risks or odds ratio
contrasts in a balanced design; where n and n(i) denote the total sample size and sample size per group (i = 0, 1) needed for testing the effect δ∗, Γ∗
or ∆∗ for a given event rate within control group p
(0)
∗ at significance level α with 1 − β power.
Variance estimator Sample Size formula
Risk difference
Pooled variance
(
p̂
(0)
∗ +p̂
(1)
∗
)(̂
q
(0)
∗ +q̂
(1)
∗
)
2n(0)
n = 2 ·
(
zα ·
√
2 p¯∗q¯∗ + zβ ·
√
p
(0)
∗ q
(0)
∗ + (p
(0)
∗ + δ∗)(q
(0)
∗ − δ∗)
)2 /
δ2∗
Unpooled variance
(
p̂
(0)
∗ q̂
(0)
∗ +p̂
(1)
∗ q̂
(1)
∗
)
n(0)
n = 2 ·
(
zα + zβ
)2 · (p(0)∗ q(0)∗ + (p(0)∗ + δ∗)(q(0)∗ − δ∗))
/
δ2∗
Risk ratio
Pooled variance 2
n(0)
· q̂
(0)
∗ +q̂
(1)
∗
p̂
(0)
∗ +p̂
(1)
∗
n = 2 ·
(
zα
√
2q¯∗
p¯∗
+ zβ
√
1−Γ∗p(0)∗
Γ∗p
(0)
∗
+
q
(0)
∗
p
(0)
∗
)2 /
log(Γ∗)2
Unpooled variance 1
n(0)
(
1−R̂∗ p̂(0)∗
R̂∗ p̂
(0)
∗
+
q̂
(0)
∗
p̂
(0)
∗
)
n = 2 ·
(
zα + zβ
)2 · ( 1−Γ∗ p(0)∗
Γ∗p
(0)
∗
+
q
(0)
∗
p
(0)
∗
) /
log(Γ∗)2
Odds ratio
Pooled variance 8
n(0)(p̂
(0)
∗ +p̂
(1)
∗ )(̂q
(0)
∗ +q̂
(1)
∗ )
n = 2 ·
(
zα
√
2
p¯
(1)
∗ q¯
(1)
∗
+ zβ ·
√
(q
(0)
∗ +p
(0)
∗ ∆∗)2
p
(0)
∗ q
(0)
∗ ∆∗
+ 1
p
(0)
∗ q
(0)
∗
)2 /
log(∆∗)2
Unpooled variance 1
n(0)
(
1
pˆ
(0)
∗ qˆ
(0)
∗
+ 1
pˆ
(1)
∗ qˆ
(1)
∗
)
n = 2 ·
(
zα + zβ
)2 · ( (q(0)∗ +p(0)∗ ∆∗)2
p
(0)
∗ q
(0)
∗ ∆∗
+ 1
p
(0)
∗ q
(0)
∗
) /
log(∆∗)2
where: p¯∗ =
p
(0)
∗ +p
(1)
∗
2
and q¯∗ =
q
(0)
∗ +q
(1)
∗
2
.
• For all (π1, π2) ∈ I1 × I2 and ρ ∈ (ρL(Θ), ρU(Θ)), it follows that:
n(π1, π2,R1,R2, ρ) ≤ UR(Θ) = n(p(0)
1
, p(0)
2
,R1,R2, ρU(Θ))
n(π1, π2,OR1,OR2, ρ) ≤ UOR(Θ) = n(p(0)
1
, p(0)
2
,OR1,OR2, ρU(Θ))
Furthermore, for given (p(0)
1
, p(0)
2
,R1,R2) or (p
(0)
1
, p(0)
2
,OR1,OR2), the sample size functions n(p
(0)
1
, p(0)
2
,R1,R2, ρ)
and n(p(0)
1
, p(0)
2
,OR1,OR2, ρ) increase with respect to the correlation ρ.
Note that, unlike when using risk differences, the sample size has its maximum value when both event rates take
their lower interval values p(0)
1
, p(0)
2
(see equations (9) and (16)).
Also note that if the marginal parameters (θ,R1,R2) or (θ,OR1,OR2) are anticipated and the correlation is not
known, the sample size strategy described in Section 4.3 can be extended to the risk and odds ratio and analogously
applied. For fixed effects (R1,R2) or (OR1,OR2), and given intervals I1 and I2 for the event rates, we can follow the
same reasoning as for risk differences in Section 4.4, and useUR(Θ) (analogouslyUOR(Θ)) to calculate the required
sample size that guarantees the planned power while accounting for the unknown correlation value and uncertainty of
the marginal parameter values.
7. A simulation study
We conduct a simulation study to evaluate the strategies proposed in Section 4 for computing the sample size.
7.1. Design
We simulate a two-arm trial with a composite primary endpoint composed of two events, ε1 and ε2, according
to the following values (which are all summarized in Table 7): the marginal probabilities of observing εk (k = 1, 2)
in the control group θ = (p
(0)
1
, p
(0)
2
) take values between 0.01 and 0.2, and they are without loss of generality such
that p
(0)
1
< p
(0)
2
; the risk ratios λ = (R1,R2) are specified for beneficial effects and vary from 0.6 to 0.8; the true
correlation between ε1 and ε2 is assumed to be common for both groups, and it covers the positive range between 0
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and 1. The possible combinations add up to a total of 421 different scenarios which take into account that for given
(θ, λ). simulations are performed only for those ρtrue between BL(θ, λ) and BU(θ, λ) (see (8)).
For each one of these 421 scenarios specified by (θ, λ, ρtrue), we compute the required sample size n(θ, λ, ρ(θ, λ))
for a one-sided test with power 1− β = 0.80 at the significance level α = 0.025, which is done by following one of the
six different formulations that are derived in Section 3 and Section 6 and, additionally, are all summarized in Table 6.
We distinguish 4 different situations according to the value we assume in ρ(θ, λ) to calculate n(θ, λ, ρ(θ, λ)):
1. For the weak correlation category, use ρ(θ, λ) = BU(θ, λ)/3
2. For the moderate correlation category, use ρ(θ, λ) = 2BU(θ, λ)/3
3. For the strong correlation category, use ρ(θ, λ) = BU(θ, λ)
4. For guessing the true correlation, use ρ(θ, λ) = ρtrue.
Given one scenario specified by (θ, λ = (R1,R2), ρtrue), we evaluate the type I error first by calculating n based on
(θ, λ = (R1,R2), ρ(θ, λ)) and simulating 100000 trials using (θ, λ = (1, 1), ρtrue). To check the power, we start by calcu-
lating n as above, based on (θ, λ = (R1,R2), ρ(θ, λ)), and then we simulate 100000 trials using (θ, λ = (R1,R2), ρtrue).
Altogether, we have to analyze a total of 3368 scenarios.
The above steps have to be reproduced six times according to the different sample size formulae used to compute
n(θ, λ, ρ(θ, λ)), that is, by stating the effect in terms of the difference in proportions, the risk ratios or the odds ratio,
and using both the pooled and the unpooled estimates of the variance. We have performed all computations using the
R software tool (Version 0.98.1087), and the time required to perform the considered simulations was 55.58h.
Table 7: Simulation scenarios: Values of marginal event rates in the control group: θ = (p
(0)
1
, p
(0)
2
); treatment effects in terms of the risk ratio:
λ = (R1,R2); and correlation ρtrue between components. Note that not all the combinations are feasible because the correlation is between BL(θ, λ)
and BU (θ, λ).
Parameter Values
p
(0)
1
0.01, 0.05, 0.10
p
(0)
2
0.01, 0.05, 0.10, 0.15, 0.20
ρtrue 0.0, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1
Effects used to evaluate the power:
R1,R2 0.6, 0.7, 0.8
Effect used to evaluate the type I error:
R1 = R2 1
7.2. Power analysis of the proposed strategies for computing sample size
Let nl,m be the required sample size calculated using the formulae described in Table 6 where l = p, u, indicating
whether the pooled or unpooled variance has been used; andm = D,R,OR, indicating the effect measure that has been
tested. In other words, for the difference in proportions, m = D; for relative risk, m = R; and for odds ratio, m = OR.
Let Ψl,m denote the empirical power when the total number of participants is nl,m (l = p, u; m = D,R,OR).
Whenever the correlation we are using to compute the sample size coincides with the one we have used to run
the simulations (ρ(θ, λ) = ρtrue), the empirical powers are always achieved whether we are using the pooled, Ψp,m,
or unpooled, Ψu,m, estimator of the variance. Nevertheless, when testing the difference in proportions, the achieved
powers do not substantially differ (Ψu,D  Ψp,D); when testing the treatment differences in terms of the risk ratio or
the odds ratio, the power achieved if the unpooled variance estimator is used is slightly larger than the power achieved
with the pooled estimator, Ψu,m ≤ Ψp,m, m = R,OR (see Table S3 in supplementary material for a comparison of the
two approaches). The results presented herein refer to the unpooled variance estimator. The corresponding results for
the pooled variance are summarized in the supplementary material (Table S4 and Figure S1).
When ρ(θ, λ) , ρtrue, we distinguish two types of misspecification. Misspecification type I, ρtrue and ρ(θ, λ) pertain
to the same correlation category; and Misspecification type II, ρtrue and ρ(θ, λ) do not belong to the same category.
14
Table 8 describes the empirical power in these two cases, which account for the correlation category for the three
effect measures that we could use to test the difference between groups. If Misspecification I occurs, the pre-specified
power is achieved and might exceed 7%.
For misspecification II, there are two possible scenarios. The first is for those cases where the correlation ρ(θ, λ)
is assumed in a stronger correlation category than the one that ρtrue belongs to, for instance, if ρ(θ, λ) is assumed to be
strong and ρtrue is moderate. Under this scenario, ρ(θ, λ) > ρtrue, and then the planned power is always achieved. The
second scenario is when the ρ(θ, λ) is assumed to be in a weaker correlation category than the one that ρtrue lies in.
For instance, when ρ(θ, λ) is assumed weak and ρtrue is moderate. In those cases where ρ(θ, λ) < ρtrue, the trial will be
underpowered.
The empirical power in terms of the difference between the assumed and true correlations is illustrated in Figure
3. Observe that when the assumed correlation is greater than the true correlation, that is, ρ(θ, λ) > ρtrue, the empirical
power is equal to or greater than the pre-specified power. Note that in all cases under the strong correlation category
we have ρtrue ≤ ρ(θ, λ), the pre-specified power is assured even though we failed to anticipate the category. Also note
that there are no differences in the achieved power, nor are there any in the method’s performance in terms of the
measure we are using to evaluate the effect.
Table 8: Median empirical power, given the sample size (under the unpooled variance), depending on the misspecification error and the assumed
correlation. Values in parentheses indicate the maximum and minimum of the empirical power.
Assumption
Misspecification I: Misspecification II:
Correlation within the category Correlation outside the category
Risk Difference
Weak 0.82 (0.80, 0.86) 0.78 (0.67, 0.80)
Moderate 0.82 (0.80, 0.87) 0.82 (0.74, 0.91)
Strong 0.82 (0.80, 0.87) 0.87 (0.81, 0.95)
Risk Ratio
Weak 0.82 (0.80, 0.86) 0.78 (0.67, 0.81)
Moderate 0.82 (0.80, 0.87) 0.82 (0.74, 0.90)
Strong 0.82 (0.80, 0.87) 0.88 (0.81, 0.95)
Odds Ratio
Weak 0.82 (0.80, 0.86) 0.78 (0.67, 0.81)
Moderate 0.82 (0.80, 0.87) 0.82 (0.74, 0.91)
Strong 0.82 (0.80, 0.87) 0.87 (0.81, 0.95)
7.3. Type I error analysis of the proposed strategies for computing sample size
The empirical results in the simulation study show that the type I error is not affected by the misspecification of the
correlation. Nonetheless, the empirical type I error under the pooled estimator may be slightly superior to significance
level 0.05, especially when the treatment is tested in terms of risk ratio and odds ratio (see Figure S3 in the online
support material).
8. Discussion
Composite endpoints are increasingly used as primary endpoints to achieve greater incidence rates of observing
the primary event, larger effect sizes and, hopefully, higher statistical power while avoiding multiplicity adjustment.
Even so, their use creates challenges in both the design and interpretation of the studies.
It is well known that sample size determination plays a key role in trial design. We have shown that calculating the
sample size for composite binary endpoints needs more than the anticipated effect size and event rates of the composite
components; it also needs the correlation between them. Sizing clinical trials in which composite endpoints are
involved often implies facing the challenge of dealing with the unknown value of the correlation. We have assessed
how much the correlation impacts the sample size and, consequently, the attained power. Our conclusion is that
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Figure 3: Scatterplot showing the relationship between empirical power versus the difference between the assumed and true correlations for each
of the sample size formulas (under unpooled variance) that were used in the simulation study in section 7.
the sample size strongly depends on the correlation and that the more correlation between the components are, the
more sample size is needed. Motivated by this concern, we have proposed some strategies for deriving the sample
size when the correlation is not specified. The strategy, based on the stratification of the correlation into different
categories, assures the pre-specified power even without previous knowledge on the correlation. In addition, if at
least we could anticipate the category where the correlation falls into, the achieved power would slightly surpass the
planned power (see Table 8). In those cases where not even the correlation category can be anticipated, the interval
of plausible values for the sample size might be too wide and the proposed strategy might be extremely conservative.
Further research is needed in such cases to obtain more accurate power.
We have illustrated our proposal using the platform CompARE. CompARE extends and includes a previous Com-
pARE web page for composite time-to-event endpoints that was created for handling the relative efficiency of com-
paring treatment groups in terms of the composite endpoint versus one of its components as the primary endpoint.
CompARE allows for the implementation of the Asymptotic Relative Efficiency method, which quantifies the gain in
efficiency from using the composite endpoint over one of its components [18, 19], doing so specifically on the basis
of information about the different endpoints and anticipated values.
Throughout this work, we have assumed that we are in the planning stage of a randomized clinical trial whose aim
is to test the efficacy of a new treatment by comparing its performance with others that have already been approved.
These trials are usually known to have much larger sample sizes. For this reason, we have restricted this work to
sample size calculation based upon asymptotic approximations of the normal distribution. In previous trial phases
devoted to obtain the optimal dose level or to study the toxicity of the new drug, the sample size is not as large as in
efficacy trials. In those cases, it could be more appropriate to base the sample size calculations on an exact test. Unlike
the tests based on asymptotic distributions, the power function of an exact test usually does not have an explicit form,
and the sample size is obtained numerically by greedy search over the sample space. In practice, the applicability
of such methods can come across difficulties because intensive computing is required[24]. There is controversy over
whether or not to use exact tests, since when the sample size is not large enough, the asymptotic test may not preserve
the test size, whereas exact tests could be conservative[25, 26, 27].
The sample size calculation in this work has been derived using the same correlations for both groups. Although
this assumption is very often being used[28, 29, 30], it remains to be studied how plausible is in practice. We are
working on an extension of our methods to account for different group correlations. Moreover, we are currently
studying and implementing in CompARE other association measures for characterizing the strength of dependence
between pairs of binary endpoints, such as the relative overlap [31], which in practice might be easier to anticipate.
Interpreting the results of a trial with a primary composite endpoint is particularly challenging. Composite end-
points comprise the information of its components and capture a more complex picture of the intervention’s efficacy,
however, they might oversimplify the evidence by looking only at the composite effect[12]. A proper study of the
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contribution from each separate component should be conducted to ensure a clear understanding of the results. What
is more, composite endpoints are in many cases formed by a set of endpoints among whom the clinical relevance
highly differs. This could lead to misleading results about whether the treatment benefits only the less important end-
points. Moreover, as shown in Section 6, the effect for the composite does not necessarily reflect the effects for the
components. CompARE computes the effect on the composite endpoint and gets constructive numerical and graphical
results in order to investigate the role that each component plays.
Comparisons between two groups when using composite endpoints could be based either on the comparison of the
corresponding proportions by means, for instance, of a two-proportion z-test or based on the comparison of survival
summaries by means, for instance, of a log-rank test. Although this paper focuses on composite binary endpoints, we
want to emphasize that time-to-first-event endpoints are very often used and that comparisons based on proportions
test could be less powerful than those based on full survival information [32, 33, 34].
Different strategies such as the win ratio[35, 36] and the weighted combined approach[37] have been developed
to take into consideration the order of clinical priorities for the composite components when analyzing composite
endpoints. Extending this work to more than two components and by incorporating weights remains open for future
research.
Acknowledgments
We would like to thank the referees for all their comments which have resulted in a clear improvement of the
manuscript. We would also like to thank Dr A. Martı´n Andre´s and the Spanish Network of Biostatistics Biostatnet
(MTM2015-69068-REDT and MTM2017-90568-REDT).
This work is partially supported by grants MTM2015-64465-C2-1-R (MINECO/FEDER) from the Ministerio de
Economı´a y Competitividad (Spain), and 2017 SGR 622 (GRBIO) from the Departament d’Economia i Coneixement
de la Generalitat de Catalunya (Spain). M. Bofill Roig acknowledges financial support from the Spanish Ministry of
Economy and Competitiveness, through the Marı´a de Maeztu Programme for Units of Excellence in R&D (MDM-
2014-0445).
Financial disclosure
None reported.
Conflict of interest
The authors declare no potential conflict of interests.
Supporting information
Additional figures and tables may be found online in the supplementary document. Source code for implementing and
reproducing the procedures discussed in this article is available at https://github.com/MartaBofillRoig/CompARE.
Appendix
Let Xi jk denote the response of the k-th binary endpoint for the j-th patient in the i-th group of treatment (i = 0, 1,
j = 1, ..., n, k = 1, 2). We denote by Xi j∗ the composite response defined as
Xi j∗ =
1, if Xi j1 + Xi j2 ≥ 10, if else Xi j1 + Xi j2 = 0 (.1)
W denote by p
(i)
1
= P(Xi j1 = 1) = 1 − q(i)1 , p(i)2 = P(Xi j2 = 1) = 1 − q(i)2 and p(i)∗ = P(Xi j∗ = 1) = 1 − q(i)∗ the
probabilities of observing each endpoint in the i-th group. Let O
(0)
k
, δk,Rk,ORk be the odds under the control group,
the risk difference, risk ratio and odds ratio, respectively, for the k-th endpoint, that is, O
(0)
k
=
p
(0)
k
q
(0)
k
, δk = p
(1)
k
− p(0)
k
,
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Rk =
p
(1)
k
p
(0)
k
, and ORk =
p
(1)
k
/q
(1)
k
p
(0)
k
/q
(0)
k
. We denote by θ = (p
(0)
1
, p
(0)
2
) the vector of marginal event rates, and λ = (δ1, δ2) the
vector of effect sizes.
Let ρ(i) represent the correlation between Xi j1 and Xi j2 in the i-th treatment group, and ρ refer to the correlation
when it is assumed to be equal in both groups, i.e., ρ = ρ(0) = ρ(1).
Appendix A. Derivation of the composite effect from the margins
We derive the expression for the composite treatment effect in terms of the marginal component and the correlation
described in Sections 2 and 6, and we prove the monotone performance of the risk difference with respect to the
correlation ρ.
Theorem Appendix A.1 (Composite effect from margins). The composite effect for the composite endpoint can be
expressed in terms of the component parameters as follows:
(i) The risk difference for the composite endpoint, δ∗, is determined by the six parameters p
(0)
1
, p
(0)
2
, δ1, δ2, ρ
(0), ρ(1)
and has the following expression:
δ∗ = δ1q
(0)
2
+ δ2q
(0)
1
− δ1δ2 + ρ(0)
√
p
(0)
1
p
(0)
2
q
(0)
1
q
(0)
2
− ρ(1)
√
(p
(0)
1
+ δ1)(p
(0)
2
+ δ2)(q
(0)
1
− δ1)(q(0)2 − δ2) (A.1)
(ii) The risk ratio for the composite endpoint, R∗, is determined by the six parameters p
(0)
1
, p
(0)
2
, R1, R2, ρ
(0), ρ(1) and
has the following expression:
R∗ =
p
(0)
1
R1 + p
(0)
2
R2 − p(0)1 p(0)2 R1R2 − ρ(1)
√
p
(0)
1
R1p
(0)
2
R2(1 − p(0)1 R1)(1 − p(0)2 R2)
1 − q(0)
1
q
(0)
2
− ρ(0)
√
p
(0)
1
p
(0)
2
q
(0)
1
q
(0)
2
(A.2)
(iii) The odds ratio for the composite endpoint, OR∗, is determined by the six parameters p
(0)
1
, p
(0)
2
, OR1, OR2, ρ
(0),
ρ(1) and has the following expression:
OR∗ =
((
1 +
OR1p
(0)
1
1−p(0)
1
) (
1 +
OR2p
(0)
2
1−p(0)
2
)
− 1 − ρ(1)
√
OR1OR2p
(0)
1
p
(0)
2
(1−p(0)
1
)(1−p(0)
2
)
)
·
(
1 + ρ(0)
√
p
(0)
1
p
(0)
2
(1−p(0)
1
)(1−p(0)
2
)
)
((
1 +
p
(0)
1
(1−p(0)
1
)
)
·
(
1 +
p
(0)
2
(1−p(0)
2
)
)
− 1 − ρ(0)
√
p
(0)
1
p
(0)
2
(1−p(0)
1
)(1−p(0)
2
)
)
·
(
1 + ρ(1)
√
OR1OR2p
(0)
1
p
(0)
2
(1−p(0)
1
)(1−p(0)
2
)
) (A.3)
Proof of Theorem Appendix A.1. (i), (ii) The two expressions (A.1) and (A.2) follow in a straightforwardmanner after
noting that:
p
(i)
∗ = 1 − q(i)1 q(i)2 − ρ(i)
√
p
(i)
1
p
(i)
2
q
(i)
1
q
(i)
2
= p
(i)
1
+ p
(i)
2
− p(i)
1
p
(i)
2
− ρ(i)
√
p
(i)
1
p
(i)
2
q
(i)
1
q
(i)
2
(A.4)
and taking into account p
(1)
k
= δk + p
(0)
k
and p
(1)
k
= p
(0)
k
R1.
(iii) Replacing the probabilities of the composite endpoint with its expression in terms of the marginal parameters
plus the correlation (A.4), we have:
OR∗ =

1 − q(1)
1
q
(1)
2
− ρ(1)
√
p
(1)
1
p
(1)
2
q
(1)
1
q
(1)
2
q
(1)
1
q
(1)
2
+ ρ(1)
√
p
(1)
1
p
(1)
2
q
(1)
1
q
(1)
2
 ·

1 − q(0)
1
q
(0)
2
− ρ(0)
√
p
(0)
1
p
(0)
2
q
(0)
1
q
(0)
2
q
(0)
1
q
(0)
2
+ ρ(0)
√
p
(0)
1
p
(0)
2
q
(0)
1
q
(0)
2

−1
=

1
q
(1)
1
q
(1)
2
− 1 − ρ(1)
√
p
(1)
1
p
(1)
2
q
(1)
1
q
(1)
2
1 + ρ(1)
√
p
(1)
1
p
(1)
2
q
(1)
1
q
(1)
2
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
1
q
(0)
1
q
(0)
2
− 1 − ρ(0)
√
p
(0)
1
p
(0)
2
q
(0)
1
q
(0)
2
1 + ρ(0)
√
p
(0)
1
p
(0)
2
q
(0)
1
q
(0)
2

−1
Notice that:
1
q
(i)
1
q
(i)
2
= (1 + O
(i)
1
)(1 + O
(i)
2
),
1
q
(1)
1
q
(1)
2
= (1 + OR1O
(0)
1
)(1 + OR2O
(0)
2
),
p
(1)
1
p
(1)
2
q
(1)
1
q
(1)
2
= OR1OR2O
(0)
1
O
(0)
2
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Hence:
OR∗ =

(1 + OR1O
(0)
1
)(1 + OR2O
(0)
2
) − 1 − ρ(1)
√
OR1OR2O
(0)
1
O
(0)
2
1 + ρ(1)
√
OR1OR2O
(0)
1
O
(0)
2
 ·

(1 + O
(0)
1
)(1 + O
(0)
2
) − 1 − ρ(0)
√
O
(0)
1
O
(0)
2
1 + ρ(0)
√
O
(0)
1
O
(0)
2

−1
By replacing O
(0)
k
by
p
(0)
k
1−p(0)
k
, we obtain (A.3). 
Theorem Appendix A.2 (Risk difference performance). Assume that p
(0)
k
< 1/2 and δk < 0 (k = 1, 2). We denote by
δ∗(ρ, θ, λ) the risk difference for the composite endpoint function described in (A.1), specifically in terms of the vector
of event rates θ, the marginal effects λ and the correlation ρ. Then, the risk difference for the composite endpoint for
a given θ and λ is an increasing function with respect to ρ.
Proof of Theorem Appendix A.2. Observe that the difference in proportions (A.1) can be written as:
δ∗(ρ, θ, λ) = x(θ, λ) + ρ · y(θ, λ).
where: x(θ, λ) = δ1q
(0)
2
+δ2q
(0)
1
−δ1δ2, and y(θ, λ) =
√
p
(0)
1
p
(0)
2
q
(0)
1
q
(0)
2
−
√
p
(1)
1
p
(1)
2
q
(1)
1
q
(1)
2
. Then: δ∗(ρ+ ǫ; θ)−δ∗(ρ; θ) =
ǫ · y(θ, λ). Therefore, δ∗(ρ; θ) is an increasing function if and only if y(θ, λ) > 0, ∀λ, θ, which is equivalent to showing
that:
p
(0)
1
p
(0)
2
q
(0)
1
q
(0)
2
p
(1)
1
p
(1)
2
q
(1)
1
q
(1)
2
> 1
It is enough to prove that for k = 1, 2,
p
(1)
k
q
(1)
k
p
(0)
k
q
(0)
k
< 1
To ease the notation call p
(1)
k
= a and p
(0)
k
= b; and, by assuming a < b < 1/2, that implies a − b < 0 and a + b < 1.
We need to prove that:
a(1 − a)
b(1 − b) =
a − a2
b − b2 < 1⇔ b − a < b
2 − a2 = (b + a)(b − a)
Since b − a > 0 and a + b < 1, then we have (a + b)(b − a) < (b − a). As a consequence y(θ, λ) > 0 and the risk
difference of the composite endpoint is an increasing function with respect to the correlation. 
Appendix B. Derivation of the sample size for the composite binary endpoint
We establish the sample size formulae for the composite endpoint in terms of the margins and derive its properties,
as outlined in Sections 4 and 6.
Appendix B.1. Sample size performance according to the correlation
Lemma Appendix B.1. Let N(p, d) denote the sample size function for testing the difference in proportions under
the unpooled variance estimate, where p denotes the probability under the control group and d the relevant difference
to be detected, that is:
N(p, d) =
( zα + zβ
d
)2
· (p · (1 − p) + (p + d) · (1 − p − d)) (B.1)
It follows that N(p, d) is an increasing function with respect to p and with respect to d.
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Proof. Observe that:
∂
∂p
N (p, d) =
(
zα + zβ
)2
(2 − 4 p − 2 d)
d2
Assuming p < 0.5, then 1 − 2p > 0 and 2 − 4p0 − 2d > 0. Therefore ∂
∂p
N (p, d) > 0, the sample size is increasing
with respect to p. Moreover,
∂
∂d
N(p, d) = −2
(
zα + zβ
)2
(p (1 − p) + (d + p) (1 − p − d))
d3
+
(
zα + zβ
)2
(1 − 2p − 2 d)
d2
Note that 1 − 2p − 2d > 0 and therefore, ∂
∂d
N(p, d) > 0; thus, the sample size is increasing with respect to d. 
Theorem 1. Let θ and λ be the vectors of, respectively, marginal event rates and effect sizes for the composite
components, and we denote by ρ the correlation between both components. Then, the sample size n(θ, λ, ρ), for a
given θ and λ is an increasing function of the correlation ρ.
Proof of Theorem 1. Since the probability of observing the composite event is given by θ and ρ (see equation (A.4)),
and the risk difference for the composite endpoint is given by λ, θ and ρ (see equation (A.1)), then the sample size for
the composite endpoint computed by n(θ, λ, ρ) = N (p∗(θ, ρ), δ∗(λ, θ, ρ)) is a function of λ, θ and ρ.
To prove that the sample size for the composite endpoint N (p∗(θ, ρ), δ∗(λ, θ, ρ)) increases with ρ, we will show
that:
∂N(p∗(θ, ρ), δ∗(λ, θ, ρ))
∂ρ
=
∂N(p∗(θ, ρ), δ∗(λ, θ, ρ))
∂p∗(θ, ρ)
· ∂p∗(θ, ρ)
∂ρ
+
∂N(p∗(θ, ρ), δ∗(λ, θ, ρ))
∂δ∗(λ, θ, ρ)
· ∂δ∗(λ, θ, ρ)
∂ρ
> 0(B.2)
From now on we will omit θ, λ and ρ and use p∗ and δ∗ instead of p∗(θ, ρ) and δ∗(λ, θ, ρ). From Lemma
Appendix B.1, the sample size N(p, d) in (B.1) is increasing with respect to the treatment effect, d, and with respect
to the probability of observing the event under control group, p, hence:
∂N(p∗, δ∗)
∂p∗
> 0 and
∂N(p∗, δ∗)
∂δ∗
> 0
We denote by:
∂p∗(θ, ρ)
∂ρ
= −a and ∂δ∗(ρ)
∂ρ
= a − b
where a, b > 0 and, from Theorem Appendix A.2, a − b > 0. Then we have:
∂N(p∗, δ∗)
∂ρ
= (a − b) ·
−2
(
zα + zβ
)2
(p∗ (1 − p∗(θ, ρ)) + (δ∗ + p∗) (1 − p∗ − δ∗))
δ∗3
+
(
zα + zβ
)2
(1 − 2 p∗ − 2δ∗)
δ∗2
 − a ·
(
zα + zβ
)2
(2 − 4 p∗ − 2δ∗)
δ∗2
and this is positive if and only if:
(a − b) ·
(
−2 p∗ (1 − p∗) + (δ∗ + p∗) (1 − p∗ − δ∗)
δ∗
+ 1 − 2p∗ − 2δ∗
)
− (2 − 4 p∗ − 2δ∗) · a (B.3)
(B.3) is positive. Then we have:
− 2 (a − b)
δ∗
(p∗ (1 − p∗) + (δ∗ + p∗) (1 − p∗ − d)) − b (1 − 2 p∗ − 2δ∗) + a (−1 + 2 p∗)
> −2 (a − b)
δ∗
p∗ (1 − p∗) − 2
(a − b)
δ∗
(δ∗ + p∗) (1 − p∗ − δ∗) − 2a (1 − p∗ − δ∗) + 2ap∗
(B.4)
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Then (B.3) ¿ (B.4), because a > b. Note that the first and forth terms are positive, so we end if we see that the second
plus third are also positive. This follows from the fact that:
−2 (a − b)
δ∗
(δ∗ + p∗) − 2a > 0 ⇔ a
(
1 +
δ∗ + p∗
δ∗
)
< b
(
δ∗ + p∗
δ∗
)
⇔ a
b
>
δ∗+p∗
δ∗
1 +
δ∗+p∗
δ∗
Since a, b > 0 and a − b > 0, we have a
b
> 1; and since
(
δ∗+p∗
δ∗
)
,
(
1 +
δ∗+p∗
δ∗
)
< 0, we have
(
δ∗+p∗
δ∗
) / (
1 +
δ∗+p∗
δ∗
)
∈ (0, 1).
Therefore (B.2) is positive, as we intended to prove. 
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